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Cardiac Rehabilitation Improves Fitness in Patients With
Subclinical Markers of Cardiotoxicity While Receiving
Chemotherapy
A RANDOMIZED CONTROLLED STUDY
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James McCord, MD; Randa Loutfi, MD; Matthew A. Saval, MS; Jodi Baxter, BS; Clinton A. Brawner, PhD;
Steven J. Keteyian, PhD

Purpose: Heart failure (HF) due to cardiotoxicity is a leading
non–cancer-related cause of morbidity and mortality in cancer
survivors. Cardiac rehabilitation (CR) improves cardiorespiratory fitness (CRF) and reduces morbidity and mortality in patients
with HF, but little is known about its effects on cardiotoxicity
in the cancer population. The objective of this study was to determine whether participation in CR improves CRF in patients
undergoing treatment with either doxorubicin or trastuzumab
who exhibit markers of subclinical cardiotoxicity.
Methods: Female patients with cancer (n = 28: breast, n = 1:
leiomyosarcoma) and evidence of subclinical cardiotoxicity (ie,
>10% relative decrease in global longitudinal strain or a cardiac
troponin of >40 ng·L−1) were randomized to 10 wk of CR or
usual care. Exercise consisted of 3 d/wk of interval training at
60-90% of heart rate reserve.
Results: Cardiorespiratory fitness, as measured by peak oxygen uptake (V̇o2peak), improved in the CR group (16.9 + 5.0
to 18.5 + 6.0 mL∙kg−1 ∙min−1) while it decreased in the usual
care group (17.9 + 3.9 to 16.9 + 4.0 mL∙kg−1 ∙min−1) (P =
.009). No changes were observed between groups with respect to
high-sensitivity troponin or global longitudinal strain.
Conclusion: This study suggests that the use of CR may be a
viable option to attenuate the reduction in CRF that occurs in
patients undergoing cardiotoxic chemotherapy. The long-term
effects of exercise on chemotherapy-induced HF warrant further
investigation.
Key Words: aerobic exercise training • cancer • cardiotoxicity •
global longitudinal strain • high-sensitivity troponin
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W

ith approximately 16 million cancer survivors in the
United States, more patients are living beyond their
initial cancer diagnosis.1 However, the increased numbers
of cancer survivors have created new challenges associated with treatment-related side effects, many of which can
impact quality of life long after treatment. Particularly concerning is cancer-related cardiotoxicity (CRC), which is the
leading noncancer cause of morbidity and mortality in cancer survivors.2,3 Although CRC can include cardiac-related
disorders such as arrhythmias, acute coronary syndrome,
and valvular disorders, the most common form of CRC
that interrupts cancer treatment is heart failure (HF) or a
decline in left ventricular ejection fraction.4 Although other
factors can contribute to this increased risk (eg, left-sided
radiation, pre-existing risk factors), HF due to CRC is often
attributed to exposure from the anticancer drugs doxorubicin and trastuzumab.5,6
The known risk for HF due to doxorubicin and trastuzumab has led to evidence-based guidelines for the surveillance and detection of cardiac dysfunction.7 However, uncertainty exists relative to who may or may not develop HF,
leading to a delicate balance between withholding these lifesaving drugs and possibly increasing the risk of irreversible
heart damage. Emerging subclinical markers such as global
longitudinal strain (GLS) and high-sensitivity cardiac troponin (hs-cTn) have helped identify patients at increased risk
for CRC8,9 but not on deciding the course of preventative
treatment. And while the use of prophylactic HF-specific
medications has been proposed, the potential for additional unwanted side effects (eg, fatigue, lightheadedness) may
negatively affect patient compliance to these HF drugs and
thus limit their efficacy.
Exercise training has shown promise as a strategy to
attenuate or improve many cancer-related side effects.10,11
Specific to cardiotoxicity, preliminary studies involving animals showed cardioprotective benefits of exercise training
when exposed to doxorubicin.12-14 The few studies in humans that have examined the effects of exercise on heart
function have involved either mostly younger individuals
with few risk factors for cardiovascular disease or have
been nonrandomized trials.15,16 There is, however, a wealth
of studies in patients with stable HF of mixed etiologies
showing that exercise training can improve exercise capacity and may favorably effect morbidity and mortality.17-20
Given the aforementioned text and the increasing evidence for exercise to attenuate certain cancer-related
side effects (eg, fatigue), we sought to determine whether
cardiac rehabilitation (CR) exercise training could improve
both exercise capacity and subclinical markers of CRC in
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individuals at risk for chemotherapy-induced HF. Our primary aim was to determine whether CR improves exercise
capacity in patients who have exhibited subclinical markers
of myocardial damage due to doxorubicin or trastuzumab.
We hypothesized that exercise training would increase exercise capacity among these patients.

METHODS
In this randomized controlled trial (ClinicalTrials.gov
NCT02796365), we recruited patients on the anticancer
therapies doxorubicin and/or trastuzumab within the Henry
Ford Health System between June 2016 and December
2018. Eligibility criteria included the ability to exercise, age
>18 yr, and a positive subclinical CRC test defined as (1)
a recent relative drop in GLS of ≥10%, or (2) a detectable standard cardiac troponin value of ≥40 ng/L. Exclusion criteria included patients with an ejection fraction of
<50%, or those with a history of either HF or coronary
artery disease. The protocol was reviewed and approved by
the Henry Ford Health System Institutional Review Board.
All subjects provided written consent.
Following baseline testing, the patients were randomized
in a 1:1 fashion to either 10 wk of CR or usual care (UC)
(Figure 1). Randomization was conducted using a computer random number generator, with group assignment transferred to allocation cards sealed in opaque sequential envelopes. Staff members who conducted the follow-up testing
at 10 wk after baseline were blinded to group assignment.
STUDY MEASURES
After providing written informed consent, the subjects completed the International Physical Activity Questionnaire
and Functional Assessment of Cancer Therapy: General
(FACT-G) questionnaires to assess physical activity status
and self-reported health, respectively. Blood samples were
collected using two 8.5-mL lithium heparin tubes: one for
immediate analysis using the standard contemporary cTnI
assay (Siemens Healthineers), and one stored at −70° C for
high-sensitivity hs-cTnI. The ADVIA Centaur high-sensitivity
cTnI assay (Siemens Healthineers) was used to measure
changes in troponin. This assay meets the requirements for
an hs-cTnI assay, as defined by the International Federation
of Clinical Applications of Cardiac Bio-Markers and the
American Association for Clinical Chemistry Academy.21
Global longitudinal strain, which characterizes left ventricular contractile function, was taken at three time points:
prior to chemotherapy (T0), at the time subclinical CRC
was detected (T1), and 10 wk following randomization (T2)
(Figure 1). The relative percent change in GLS was calculated using the T0 measurement as the reference. All subjects
had a GLS (which is expressed as a negative number) prior
to chemotherapy at T0. A relative reduction of 10% when
compared with the pre-treatment echocardiogram (T0) was
considered eligible for the study (example GLS at T0 =

−20%, GLS at T1 = −17%, relative change −3/−20 = 15%
reduction). All echocardiographic testing was done at Henry
Ford Hospital by an experienced technician, using a Vivid
E9 system (General Electric Company). Digital images were
saved and off-line 2D-STE analyses were performed using the
ECHOPAC, version 201. For all patients, optimal apical 2D
images were obtained with frame rates between 50 and 80
Hz in grayscale. The software did not quantify strain if there
was significant heart rate variability. Left ventricular ejection
fraction was calculated using the biplane Simpson method.
The LV longitudinal strain parameters were measured from
the apical four-chamber, two-chamber, and three-chamber
views. The region of interest was kept off the blood pool and
adjusted to cover at least 90% of the myocardial wall thickness. Global longitudinal strain was reported using the same
software (ECHOPAC) on all follow-up studies. Studies were
performed and reported according to the document of the
European Association of Cardiovascular Imaging/American
Society of Echocardiography/Industry Task Force.22
Prior to cardiopulmonary exercise testing (CPX), resting
heart rate and resting oxygen uptake (V̇o2) were measured
during the last minute of 3 min of seated rest. Expired air
was sampled breath by breath and analyzed using an MGC
Diagnostics metabolic cart. The CPX was performed using
the Haskell treadmill protocol (ie, two metabolic equivalents
of task increase for every 3-min stage). During the CPX, the
patients were encouraged to exercise until reaching a sign or
symptom-limited maximum. Gas exchange and heart rate
data were reported in 30-sec interval averages. Peak values
were the highest interval value during the last minute of exercise or the first interval of recovery. The CPX data were analyzed by the Henry Ford core laboratory using standardized
procedures. Core laboratory staff were blinded to treatment
group and not involved in the conduct of the CPX.
INTERVENTION
Exercise training was performed at three Henry Ford Health
System CR sites in the Detroit Metropolitan area (ie, one urban and two suburban locations). Subjects participated in the
phase II CR program offered 2 or 3 d/wk, for 10 wk (30 visits)
and had the option to attend CR education lectures on various
wellness topics (eg, nutrition, stress management, cardiac medications). Exercise training consisted of interval training protocol with 4-min high-intensity intervals alternated by 3 min of
moderate intensity. Exercise intensity was guided using the heart
rate reserve method with high intensity set at 71-90% heart rate
reserve and moderate intensity at 60-70%. The exercise sessions
were 40-50 min of duration and subjects performed one to two
exercise modalities (eg, treadmill, stationary cycle, elliptical
trainer). A 5-min warm-up and cooldown was performed at the
beginning and end of each workout session.
Patients randomized into the UC group were not given an
individualized exercise prescription to follow or counseled
about physical activity but were told to continue to follow
physician instructions regarding care, including any physical

Figure 1. HF PROACTIVE study design. aEchocardiogram obtained prior to chemotherapy. Abbreviations: CRC, cancer related cardiotoxicity; CPX,
cardiopulmonary exercise test.
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activity recommendations. To partially control for patient
contact, both groups received a biweekly follow-up call from
the research coordinator asking about any changes in health.
Untoward events were recorded during biweekly follow-up
phone calls by research staff or sent directly via electrical
medical records notification (ie, EPIC research alerts).
STATISTICAL ANALYSIS
Utilizing a Per Protocol Analysis, a Student t test and the χ2
test were used to compare groups at baseline for continuous and nominal data, respectively. A paired t test was used
to assess within-group changes from T1 to T2. An independent sample t test was used to compare the differences
in change from baseline to follow-up between UC and CR
groups. Alpha level was set at .05. All statistical analyses
were performed with SPSS version 21.0 (IBM Corp).

RESULTS
As shown in Figure 2, the main reasons candidates were
ineligible were due to not being on a cardiotoxic anticancer
drug (ie, doxorubicin or trastuzumab), already completed
cancer treatment, or did not have a ≥10% relative drop in
GLS from the echocardiography done before chemotherapy. Of those who met the eligibility criteria but declined
participation, 23% stated concerns regarding the inability
to exercise during treatment, while 36% were not available
to exercise because of work/schedule conflicts or distance/
travel reasons (Figure 2). Baseline characteristics of all participants can be found in Table 1.
The attrition rate between the CR group and the UC
group was similar (21% UC vs 27% CR) and was related to health concerns/treatment side effects, work schedule
conflicts, or travel/distance concerns. Of those randomized
into the CR group, the average attendance rate was 70% of
all scheduled visits. Adherence to the high intensity interval training exercise protocol was 59%, based on the percentage of CR sessions where subjects achieved at least one

interval within the exercise training heart rate between 70%
and 90% of heart rate reserve. Reasons for not reaching the
prescribed heart rate reserve include chemotherapy-induced
peripheral neuropathy, fatigue, and joint/orthopedic pain.
However, despite one-third of the exercise sessions not
reaching the prescribed high-intensity zone, in 81% of the
CR sessions a heart rate reserve of ≥60% was achieved,
which was the minimally prescribed training target.
MEASURES
The effects of exercise training for the CR group are shown
in Table 2 and Figures 3 and 4. In general, the CR group
showed improvements in CRF as measured by within- and
between-group increases in V̇o2peak and within-group improvements for CPX duration and ventilatory threshold.
Conversely, the control group showed a within-group decrease in V̇o2peak, as well as trends suggesting decreases in
exercise time and ventilatory threshold.
The decrease in GLS for the UC group dropped from −21%
to −16.7% (20% reduction) and for the CR group changed
from −19.3% to −16.4% (15% reduction) (Figure 4).
And although both groups showed time-dependent
within-group improvements in GLS from T1 to T2, no
statistical differences were found between groups. The HscTnI showed a within-group trend toward improvement for
the CR group; however, this was not significant and there
were no differences between groups (P = .230).
Patient-reported quality of life, as defined by the FACT-G
questionnaire, showed a trend toward improvement among
both the control and CR groups (Table 2); however, there
was no significant difference in changes between groups
(P = .556). No differences were found within or between
the subdomains of the FACT-G (ie, functional, physical, social/family, and emotional).
ADVERSE EVENTS
Untoward events were defined as any unexpected condition requiring medical attention, which necessitated a visit

Figure 2. Consort diagram of study participant flow. Abbreviations: CVD, cardiovascular disease; GLS, global longitudinal strain.
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Table 1
Demographicsa
P Value

Variable

Treatment

Control

Total, N

11

11

Age, yr

58 ± 11

52 ± 13

.756

Rest systolic blood pressure, mm Hg

121 ± 13

115 ± 13

.314

Rest diastolic blood pressure, mm Hg

76 ± 8

68 ± 8

.030b

Rest heart rate, bpm

71 ± 10

74 ± 13

.599

Body mass index, kg∙m−2

31 ± 7

34 ± 5

.377

Breast cancer

10 (92)

11 (100)

.702

Stage 1

0 (0)

3 (27)

Stage 2

8 (72)

5 (45)

Stage 3

2 (18)

2 (18)

Stage 4

1 (9)

1 (9)

62 ± 6

58 ± 3

.100

−16.7 ± 4.0

−16.4 ± 1.6

.809

24.9 ± 43.8

15.6 ± 25.3

.490

β-blockers

4 (36)

3 (27)

.647

ACEI/ARBs

6 (55)

4 (36)

.392

Doxorubicin

6 (55)

4 (36)

.201

Trastuzumab

8 (72)

11 (100)

.331

Cancer stage

Ejection fraction, %
Global longitudinal strain, %
−1

High-sensitivity troponin, ng L
Cardiovascular medication

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers.
a
Data presented as mean ± SD or n (%).
b
Differences between groups: ≤0.05.

Table 2
Exercise Performance, Patient-Reported Health Status, and Troponin Measuresa
Cardiac Rehabilitation

Usual Care
T1

T2

P Value

1.6 ± 0.3

1.5 ± 0.3

1.4 ± 0.3

.012c

16.9 ± 5.0

18.5 ± 6.0b

17.9 ± 3.9

16.9 ± 4.0

.005c

85 ± 15

92 ± 18b

85 ± 13

81 ± 10

.004c

Ventilatory threshold, mL∙kg−1∙min−1

11.4 ± 3.2

12.5 ± 3.7b

12.2 ± 2.1

11.3 ± 1.5

.092

Peak RER

1.15 ± 0.09

1.17 ± 0.08

1.16 ± 0.1

1.21 ± 0.1

.491

VE/VCO2

33.2 ± 5.6

34.2 ± 4.4

32.7 ± 4.3

31.8 ± 4.1

.141

Peak HR, bpm

150 ± 16

148 ± 19

150 ± 20

150 ± 15

.819

Total exercise time, min

9.1 ± 2.5

11.5 ± 4.3b

9.6 ± 2.2

10.1 ± 2.7

.060

FACT-G

82.6 ± 11.6

86.2 ± 14.4

72.4 ± 11.7

79.6 ± 13.6

.556

High-sensitivity troponin, ng·L−1

24.6 ± 43.8

13.9 ± 14.9

15.6 ± 25.3

27.1 ± 60.8

.211

Characteristic

T1

T2

V̇o2peak, L∙min

1.5 ± 0.2

V̇o2peak, mL∙kg−1∙min−1

−1

Percent-predicted V̇o2peak, %

b

Abbreviations: FACT, Functional Assessment of Cancer Therapy—General; HR, heart rate; RER, respiratory exchange ratio; VE/VCO2, slope of the ratio of minute ventilation to carbon dioxide;
V̇o2, oxygen uptake.
a
Data are presented as mean ± SD.
b
Differences within groups ≤0.05.
c
Differences between groups: ≤0.05.
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Figure 3. Individual V̇o2peak changes over 10 wk. Dotted lines indicate group mean. Abbreviation: CR, cardiac rehabilitation. This figure is available in
color online (www.jcrpjournal.com ).

to a physician or the emergency department. None of the
patients, regardless of study assignment, were admitted to
the hospital during this study. Furthermore, aside from adjusting workload and/or exercise modality due to fatigue or
neuropathy pain, no exercise session was stopped because
of an untoward event. A total of six non–exercise-related
untoward events were recorded (three in each group). The
nature of these events was as follows: for the control group,
these included hypokalemia, dermatitis, and dehydration;
for the CR group, this included a near syncopal episode, an
urinary tract infection, and a fall at home.

DISCUSSION
This study supports the utilization of CR to perform exercise training in patients exposed to cardiotoxic cancer treatments and is the first to our knowledge to demonstrate improvement of V̇o2peak among individuals with early signs and
symptoms of cardiotoxicity. The improvement of V̇o2peak in
the CR group is potentially important because of the known
association with mortality and poor CRF23; thus, increases
in CRF may reduce the risk of HF as well as other CV events.
The lack of improvement observed for the GLS (Figure 4)
may be due to several factors including the timing of the

intervention, the sensitivity of these tests, and/or the length
of the training stimulus itself. Regarding the timing of the
exercise intervention, it may be that exercise training prior
to exposure to the toxic agent (ie, the so-called “pre-hab”)
might have more of an impact with respect to the GLS and
troponin values. This is supported by Chicco et al,12 who
showed that exercise training performed before doxorubicin exposure in rats attenuated the loss in left ventricular
function observed in the control group.
The relatively short length of the training as well as the
follow-up may be another reason why no difference was
found between groups. A recent study by Ansund et al24
found that NT-pro-BNP levels were improved at 1-yr
follow-up in a group of individuals who self-selected to participate in high-intensity interval training.
Alternatively, a reason why cardiopulmonary fitness improved independent of GLS or troponin is that the observed
improvements with exercise training might be a result of peripheral adaptations (eg, improved capillary density, aerobic
enzymes, and mitochondria density). This is supported in
studies showing a discordance between V̇o2peak and left ventricular function.25,26
Furthermore, there is potential concern that exercise
while actively undergoing cardiotoxic chemotherapy may

Figure 4. Change in global longitudinal strain. aDifferences within groups ≤ 0.05. This figure is available in color online (www.jcrpjournal.com ).
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be detrimental to the heart. This is supported by an observational study by Haykowsky et al16 reporting a modest,
but significant, reduction in left ventricular ejection fraction
in patients while exercise training during treatment with
trastuzumab. Despite that finding, we did not observe any
decrease in cardiac function with exercise training.
In addition to the direct effects of cancer-related cardiotoxicity, there is growing interest with respect to the greater
downstream heart disease risk in patients with cancer.27,28
Because exercise training has been shown to improve many
CV risk factors, it has been promoted to potentially mitigate
heart disease in the cancer population. The barrier, however, that many patients, and referring oncologists, face is that
there are not very many cancer-specific exercise programs in
the country. However, the existing network of CR programs
can help bridge this gap, providing them with facilities and
staff in a scalable fashion to meet the growing demands of an
increasing survivorship population. Our study demonstrated
from a feasibility standpoint that CR can fill that need.
The strengths of this study were that we had a clearly defined higher-risk cohort, it was a randomized controlled trial, and that the exercise training was supervised by clinical
exercise physiologists in an evidence-based setting (ie, CR).
Potential limitations to this study include the small sample
size, the short duration of training (10 wk), the short follow-up period (ie, 3 mo), and perhaps the transient nature
of these biomarkers, which often trend back to normal as
the time increases from the insult to the myocardium. In addition, the small number of patients with elevated troponins
at baseline may have been a large contributing factor to
why no differences were observed between groups.
In conclusion, our study suggests that CR is potentially a viable pathway to improve exercise capacity in
patients undergoing treatment with known cardiotoxic
agents. Future studies should include a larger number of
participants across multiple health locations and have a
longer follow-up period.
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